ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
Copenhagen N |
NA | |
(Address of principal executive offices) |
(Zip Code) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
Emerging growth company |
Exhibit Number |
Description | |
31.1+ | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2+ | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | |
101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* | Previously filed. |
+ | Filed herewith. |
† | Indicates a management contract or compensatory plan or arrangement. |
# | Portions of the exhibit have been or will be excluded because it is both not material and is the type of information that the registrant treats as private or confidential. |
IO Biotech, Inc. | ||||||
Date: March 22, 2024 | By: | /s/ Mai-Britt Zocca | ||||
Mai-Britt Zocca, Ph.D. | ||||||
Chief Executive Officer and Director (Principal Executive Officer) |
Name |
Title |
Date | ||
/s/ Mai-Britt Zocca, Ph.D.Mai-Britt Zocca, Ph.D. |
Chief Executive Officer and Director (Principal Executive Officer) |
March 22, 2024 | ||
/s/ Amy Sullivan, M.B.A. Amy Sullivan, M.B.A. |
Chief Financial Officer (Principal Financial Officer) |
March 22, 2024 | ||
/s/ Brian Burkavage Brian Burkavage |
Vice President of Finance (Principal Accounting Officer) |
March 22, 2024 | ||
/s/ Peter Hirth, Ph.D.* |
Chairman of the Board | March 5, 2024 | ||
Peter Hirth, Ph.D. |
||||
/s/ Kathleen Sereda Glaub, M.B.A.* |
Director | March 5, 2024 | ||
Kathleen Sereda Glaub, M.B.A. |
||||
/s/ Christian Elling, Ph.D.* |
Director | March 5, 2024 | ||
Christian Elling, Ph.D. |
||||
/s/ Helen Collins, MD* |
Director | March 5, 2024 | ||
Helen Collins, MD |
||||
/s/ Jack B. Nielsen* |
Director | March 5, 2024 | ||
Jack B. Nielsen |
||||
/s/ Heidi Hunter* |
Director | March 5, 2024 | ||
Heidi Hunter |
||||
/s/ David V. Smith, M.B.A.* |
Director | March 5, 2024 | ||
David Smith, M.B.A. |